RU2017123243A - Состав, содержащий экстракт кожицы poria cocos, предназначенный для профилактики, облегчения состояния и лечения нейродегенеративных расстройств - Google Patents
Состав, содержащий экстракт кожицы poria cocos, предназначенный для профилактики, облегчения состояния и лечения нейродегенеративных расстройств Download PDFInfo
- Publication number
- RU2017123243A RU2017123243A RU2017123243A RU2017123243A RU2017123243A RU 2017123243 A RU2017123243 A RU 2017123243A RU 2017123243 A RU2017123243 A RU 2017123243A RU 2017123243 A RU2017123243 A RU 2017123243A RU 2017123243 A RU2017123243 A RU 2017123243A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- prevention
- degenerative neurological
- treatment
- poria cocos
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims 11
- 239000000203 mixture Substances 0.000 title claims 10
- 235000008599 Poria cocos Nutrition 0.000 title claims 9
- 241001619444 Wolfiporia cocos Species 0.000 title claims 9
- 238000011282 treatment Methods 0.000 title claims 9
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 claims 13
- 208000025966 Neurological disease Diseases 0.000 claims 13
- 230000003412 degenerative effect Effects 0.000 claims 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 235000013305 food Nutrition 0.000 claims 6
- 238000000605 extraction Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000000750 progressive effect Effects 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Claims (11)
1. Фармацевтическая композиция для профилактики или лечения дегенеративных неврологических заболеваний, содержащая в качестве действующего вещества экстракт кожицы Poria cocos.
2. Фармацевтическая композиция для профилактики или лечения дегенеративного неврологического заболевания по п. 1, где дегенеративное неврологическое заболевание представляет собой заболевание из группы, в которую входят болезнь Альцгеймера, болезнь Крейтцфельдта-Якоба, болезнь Хантингтона, рассеянный склероз, синдром Гийена-Барре, болезнь Паркинсона, болезнь Лу Герига, прогрессирующая деменция, вызванная постепенной гибелью нейронов, и прогрессирующая атаксия.
3. Фармацевтическая композиция для профилактики или лечения дегенеративного неврологического заболевания по п. 1, в которой экстракт кожицы Poria cocos получен экстракцией водой, или низшим спиртом, имеющим от 1 до 4 атомов углерода, или их смесью.
4. Фармацевтическая композиция для профилактики или лечения дегенеративного неврологического заболевания по п. 1, в которой экстракт кожицы Poria cocos получен экстракцией этанолом в концентрации 60-80% (по объему).
5. Пищевая композиция для профилактики или лечения дегенеративного неврологического заболевания, содержащая в качестве действующего вещества экстракт кожицы Poria cocos.
6. Пищевая композиция для профилактики или улучшения дегенеративного неврологического заболевания по п. 5, где дегенеративное неврологическое заболевание представляет собой заболевание из группы, в которую входят болезнь Альцгеймера, болезнь Крейтцфельдта-Якоба, болезнь Хантингтона, рассеянный склероз, синдром Гийена-Барре, болезнь Паркинсона, болезнь Лу Герига, прогрессирующая деменция, вызванная постепенной гибелью нейронов и прогрессирующая атаксия.
7. Пищевая композиция для профилактики или лечения дегенеративного неврологического заболевания по п. 5, в которой экстракт кожицы Poria cocos получен экстракцией водой, или низшим спиртом, имеющим от 1 до 4 атомов углерода, или их смесью.
8. Пищевая композиция для профилактики или улучшения дегенеративного неврологического заболевания по п. 5, в которой экстракт кожицы Poria cocos получен экстракцией этанолом в концентрации 60-80% (по объему).
9. Пищевая композиция для профилактики или улучшения дегенеративного неврологического заболевания по любому из пп. 5-8, где пищевая композиция представляет собой функциональный оздоровительный продукт или функциональный оздоровительный напиток.
10. Способ профилактики, улучшения состояния или лечения дегенеративного неврологического заболевания, заключающийся в назначении композиции, содержащей в качестве действующего вещества экстракт кожицы Poria cocos.
11. Применение экстракта кожицы Poria cocos для профилактики, улучшения состояния или лечения дегенеративного неврологического заболевания.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2014-0184853 | 2014-12-19 | ||
| KR1020140184853A KR101698163B1 (ko) | 2014-12-19 | 2014-12-19 | 복령피 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
| PCT/KR2015/013136 WO2016099056A2 (ko) | 2014-12-19 | 2015-12-03 | 복령피 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017123243A3 RU2017123243A3 (ru) | 2019-01-21 |
| RU2017123243A true RU2017123243A (ru) | 2019-01-21 |
| RU2678982C2 RU2678982C2 (ru) | 2019-02-05 |
Family
ID=56127796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017123243A RU2678982C2 (ru) | 2014-12-19 | 2015-12-03 | Состав, содержащий экстракт кожицы poria cocos, предназначенный для профилактики, облегчения состояния и лечения нейродегенеративных расстройств |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10864238B2 (ru) |
| EP (2) | EP3235502B1 (ru) |
| JP (1) | JP6533294B2 (ru) |
| KR (1) | KR101698163B1 (ru) |
| CN (2) | CN113712998A (ru) |
| BR (1) | BR112017012909B1 (ru) |
| CY (2) | CY1123293T1 (ru) |
| DK (2) | DK3632454T3 (ru) |
| HU (2) | HUE049254T2 (ru) |
| RU (1) | RU2678982C2 (ru) |
| SI (2) | SI3632454T1 (ru) |
| WO (1) | WO2016099056A2 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6844829B2 (ja) * | 2016-07-21 | 2021-03-17 | 日本メナード化粧品株式会社 | 幹細胞の未分化状態維持剤及び増殖促進剤 |
| MY195806A (en) * | 2016-09-06 | 2023-02-22 | Sinphar Tian Li Pharmaceutical Co Ltd Hangzhou | Use of Poria Extract and Active Ingredient Thereof in Skin Care and/or Promoting Wound Healing |
| CN111759915A (zh) * | 2020-07-20 | 2020-10-13 | 南通大学 | 一种神经再生复方制剂及其制备方法和用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ192673A (en) * | 1979-02-02 | 1984-07-06 | Merck & Co Inc | Ophthalmic compositions for lowering intraocular pressure |
| EP0970702A4 (en) * | 1996-02-15 | 2000-01-12 | Daiichi Seiyaku Co | FACTORS THAT ACTIVATE THE BRAIN |
| KR100615389B1 (ko) * | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| KR100526628B1 (ko) | 2003-03-21 | 2005-11-08 | 주식회사 에스티씨나라 | 모노아민산화효소 저해활성을 갖는 상심자 추출물을함유한 조성물 |
| KR20050092292A (ko) * | 2004-03-15 | 2005-09-21 | 주식회사 크라우젠 | 기억력 증강 효과가 있는 생약재 조성물 |
| KR100779179B1 (ko) * | 2006-05-19 | 2007-11-28 | 충북대학교 산학협력단 | 토복령의 메탄올 추출물을 함유하는 뇌신경 보호 또는퇴행성뇌질환 예방 또는 치료제 |
| KR100847343B1 (ko) * | 2006-12-08 | 2008-07-21 | 경희대학교 산학협력단 | 생약복합재 추출물을 함유하는 골길이 성장 촉진용 조성물 |
| CN101152554A (zh) | 2007-09-24 | 2008-04-02 | 徐大洋 | 治疗荨麻疹既泄热消疹的中药 |
| KR20090071704A (ko) * | 2007-12-28 | 2009-07-02 | 퓨리메드 주식회사 | 치매 예방 및 치료용 조성물 |
| KR101072662B1 (ko) * | 2008-12-18 | 2011-10-11 | 대구한의대학교산학협력단 | 복신 건조분말 또는 그 추출물을 유효성분으로 함유하는건망증 및 기억력 장애 관련 질환의 예방 및 치료용 조성물 |
| KR101064258B1 (ko) | 2008-12-29 | 2011-09-14 | 한국과학기술연구원 | 벤조아릴우레이도 화합물, 및 이를 함유하는 퇴행성 뇌질환예방 또는 치료용 조성물 |
| KR20100083632A (ko) * | 2009-01-14 | 2010-07-22 | 울산대학교 산학협력단 | 표적 단백질 분해효소 감응형 항암제 전구체 |
| KR20110119983A (ko) | 2010-04-28 | 2011-11-03 | 순천대학교 산학협력단 | 뽕나무 열매 추출물을 함유하는 아세틸콜린에스테라제 억제용 조성물 |
| CN102133351B (zh) | 2011-03-04 | 2012-05-09 | 费萍 | 一种治疗阿尔茨海默病的药物组合物及其制备方法 |
| CN102133242B (zh) * | 2011-03-07 | 2013-12-11 | 北京中医药大学 | 一种茯苓提取物及其制备方法 |
| JP2013234178A (ja) | 2012-04-12 | 2013-11-21 | Kracie Seiyaku Kk | 細胞死抑制組成物 |
| KR101251866B1 (ko) | 2012-07-12 | 2013-04-10 | 순천대학교 산학협력단 | 뽕나무 열매 추출물을 함유하는 아세틸콜린에스테라제 억제용 조성물 |
| WO2014088200A1 (ko) * | 2012-12-06 | 2014-06-12 | 한국식품연구원 | 복령피 추출물, 백미 추출물 또는 남성 추출물을 유효성분으로 포함하는 면역 질환의 예방, 개선 또는 치료용 조성물 |
| KR101577392B1 (ko) * | 2012-12-06 | 2015-12-17 | 한국식품연구원 | 복령피 추출물을 유효성분으로 포함하는 Ｔｈ1-매개 면역 질환 또는 Ｔｈ2-매개 면역 질환의 예방, 개선 또는 치료용 조성물 |
| CN103393809B (zh) * | 2013-07-24 | 2015-01-07 | 张立东 | 治疗帕金森的药物 |
| CN104013891A (zh) * | 2014-05-28 | 2014-09-03 | 高益槐 | 一种益智健脑的复方制剂及其制备方法 |
| KR101671437B1 (ko) | 2014-12-19 | 2016-11-01 | 동아에스티 주식회사 | 상심자 및 복령피 혼합 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
-
2014
- 2014-12-19 KR KR1020140184853A patent/KR101698163B1/ko active IP Right Grant
-
2015
- 2015-12-03 BR BR112017012909-4A patent/BR112017012909B1/pt active IP Right Grant
- 2015-12-03 WO PCT/KR2015/013136 patent/WO2016099056A2/ko active Application Filing
- 2015-12-03 CN CN202111105525.8A patent/CN113712998A/zh active Pending
- 2015-12-03 DK DK19210811.6T patent/DK3632454T3/da active
- 2015-12-03 SI SI201531724T patent/SI3632454T1/sl unknown
- 2015-12-03 EP EP15870223.3A patent/EP3235502B1/en active Active
- 2015-12-03 JP JP2017532138A patent/JP6533294B2/ja active Active
- 2015-12-03 DK DK15870223.3T patent/DK3235502T3/da active
- 2015-12-03 HU HUE15870223A patent/HUE049254T2/hu unknown
- 2015-12-03 SI SI201531202T patent/SI3235502T1/sl unknown
- 2015-12-03 CN CN201580069243.3A patent/CN107106620A/zh active Pending
- 2015-12-03 RU RU2017123243A patent/RU2678982C2/ru active
- 2015-12-03 HU HUE19210811A patent/HUE056404T2/hu unknown
- 2015-12-03 US US15/535,478 patent/US10864238B2/en active Active
- 2015-12-03 EP EP19210811.6A patent/EP3632454B1/en active Active
-
2020
- 2020-05-25 CY CY20201100474T patent/CY1123293T1/el unknown
- 2020-11-13 US US17/097,592 patent/US20210128656A1/en not_active Abandoned
-
2021
- 2021-11-02 CY CY20211100941T patent/CY1124945T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3632454A1 (en) | 2020-04-08 |
| CN113712998A (zh) | 2021-11-30 |
| EP3235502A2 (en) | 2017-10-25 |
| DK3235502T3 (da) | 2020-06-02 |
| EP3235502B1 (en) | 2020-02-26 |
| EP3632454B1 (en) | 2021-08-11 |
| KR101698163B1 (ko) | 2017-01-19 |
| WO2016099056A3 (ko) | 2016-08-11 |
| BR112017012909A2 (pt) | 2018-01-09 |
| JP6533294B2 (ja) | 2019-06-19 |
| HUE056404T2 (hu) | 2022-02-28 |
| US20170368122A1 (en) | 2017-12-28 |
| CY1124945T1 (el) | 2023-01-05 |
| RU2017123243A3 (ru) | 2019-01-21 |
| RU2678982C2 (ru) | 2019-02-05 |
| HUE049254T2 (hu) | 2020-09-28 |
| SI3632454T1 (sl) | 2021-11-30 |
| JP2018500331A (ja) | 2018-01-11 |
| DK3632454T3 (da) | 2021-11-08 |
| US20210128656A1 (en) | 2021-05-06 |
| BR112017012909B1 (pt) | 2021-06-15 |
| CN107106620A (zh) | 2017-08-29 |
| CY1123293T1 (el) | 2021-12-31 |
| KR20160075183A (ko) | 2016-06-29 |
| WO2016099056A8 (ko) | 2017-06-29 |
| EP3235502A4 (en) | 2018-07-18 |
| SI3235502T1 (sl) | 2020-07-31 |
| US10864238B2 (en) | 2020-12-15 |
| WO2016099056A2 (ko) | 2016-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| PH12016501307B1 (en) | Compounds | |
| MY192840A (en) | Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling glucide and/or lipid metabolism | |
| ZA202001057B (en) | Inhibiting ubiquitin specific peptidase 30 | |
| BR112016023382A2 (pt) | composto, medicamento, método para inibir lsd1, e, uso de um composto | |
| WO2015101957A3 (en) | Inhibitors of glutaminase | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| MX2016002241A (es) | Alcoholes de alquinilo y metodos de uso. | |
| WO2015200790A3 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| WO2017053868A8 (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| BR112015022041A2 (pt) | derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas | |
| WO2018111315A8 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | |
| HRP20211100T1 (hr) | Sastav koji sadrži miješani ekstrakt murve i kore poria kokosa za prevenciju, poboljšanje ili liječenje neurodegenerativnih bolesti | |
| PH12016501584B1 (en) | Composition for improving blood circulation, containing extract of lindera obtusiloba as active ingredient | |
| NZ702742A (en) | Camsylate salt of (1r,1’r,4r)- 4-methoxy-5’’-methyl-6’-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3’h-dispiro[cyclohexane-1,2’-indene-1’,2’’-imidazol]-4’’-amine | |
| WO2015120372A3 (en) | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases | |
| MX2017003470A (es) | Inhibidores macrociclicos de cinasa lrrk2. | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| RU2017123243A (ru) | Состав, содержащий экстракт кожицы poria cocos, предназначенный для профилактики, облегчения состояния и лечения нейродегенеративных расстройств | |
| WO2016080796A3 (ko) | 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도 | |
| JP2016524608A5 (ru) | ||
| SG11201902987SA (en) | Use of idhp in preparation of drug or health product for prevention and treatment of coronary atherosclerosis disease | |
| WO2016005962A3 (en) | Stable liquid formulations of cyclophosphamide and processes | |
| PH12016502006B1 (en) | A prodrug of 1,1`-(1,6-dioxo-1,6-hexanediyl)bis-d-proline | |
| EP3616704A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S MORBUS WITH GINSENG EXTRACT FROM MOUNTAIN FARMING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20200630 |